The multidrug resistance (MDR) mediated by P-glycoprotein (P-gp), the MDR1 gene product, is one of the major obstacles in leukemia treatment. The present study was designed to explore a MDR1-targeted small interfering RNA (si-MDR1) approach for reversal of P-gp-mediated MDR in the MDR human leukemia cell line k562/A02. It was found that si-MDR1 significantly inhibited MDR1 expression at both mRNA and protein levels. Depletion of MDR1 by si-MDR1 correlated with the increased sensitivity of the cells to cytotoxic agents and with the enhanced intracellular retention of daunorubicin (DNR). One base-pair mutated control (si-MDR1-Mut) lost the effect of si-MDR1 on both the degradation of mdr1 mRNA and the reduction of P-gp expression. These findings indicate that siRNA specifically and efficiently interferes with the expression of mdr1 and could be used as a molecularly defined therapeutic approach for MDR in the treatment of leukemia.
A major cause of treatment failure in hematological malignancies is the emergence of drug-resistant cells, either at diagnosis or at the time of relapse. The multidrug resistance (MDR) phenotype, defined by a cross-resistance to a number of functionally and structurally distinct drugs, is currently the best-understood mechanism of cellular resistance. The MDR phenotype is related to the overexpression of the MDR1 gene product, a 170-kDa transmembrane p-glycoprotein (P-gp). The ATP-dependent unidirectional drug-efflux pump decreases the intracellular retention of many cytotoxic agents, such as anthracyclines, which are of eminent importance in the treatment of acute myeloid leukemia (AML). On this base, several approaches capable of inhibiting P-gp activity or the expression the P-gp-specific MDR1 mRNA, including P-gp modulator, antisense oligonucleotides and hammerhead ribozymes, have been described. [1] [2] [3] [4] [5] However, the clinical benefit of these approaches remains to be explored.
It has recently been discovered that double-stranded RNA-mediated interference has emerged as a powerful reverse genetic tool to silence gene expression in multiple organisms even in human cells. 6 One of the obstacles to achieving RNAi in mammals is that dsRNAs longer than 30 nt will activate an antiviral response, leading to the nonspecific degradation of RNA transcripts and a general shutdown of host cell protein translation. 7 This obstacle has been recently overcome by Tuschl and colleagues, 8 who found that gene-specific suppression in mammalian cells could be achieved by vitro-synthesized siRNA with 21 nt in length, long enough to induce gene-specific suppression, but short enough to evade the host interferon response. Beyond their value for target validation, siRNAs hold great potential as gene-specific therapeutic agents. Here, we report that siRNA effectively inhibited the expression of MDR1 mRNA and P-gp and restored MDR in K562/A02 cells, consistent with the works of others 9 in solid tumor cell lines. Our data indicate that RNAi is a specifically pathway in the reversal of MDR and may be utilized as a novel therapeutic approach to leukemia and other malignancies.
Materials and methods

Cell line and cell culture
The erythroblastic leukemia cell line K562 cells and the MDR human acute myelogenous leukemia cell line K562/ A02 10, 11 were used in the study. The native K562 and K562/A02 cells were maintained in RPMI 1640 medium (GIBCO, Grand Island, NY) containing 10% fetal calf serum (FCS), 100 U/ml penicillin, and 100 mg/ml streptomycin at 371C in a humidified atmosphere containing 5% CO 2 . A measure of 1 mg/ml doxorubicin was added to the medium for the maintenance of the MDR phenotype of K562/A02.
siRNA synthesis and transfection
According to the procedure described by Wilda et al 12 and the Tuschl laboratory (http://www.mpibpc.gwdg.de/ abteilungen/100/105/siRNAuserguide.pdf), the target sequence which homologous to nt (445-465, 2472-2492, 3564-3574) of the MDR1 mRNA sequence (GenBank accession number AF016535) was chosen (Fig 1a) . The siRNAs were prepared using Silencert siRNA Construction Kit (Ambion, Austin, TX) according to the instruction manual exactly. The random sequence control siRNA was purchased from Ambion, Austin, TX (Silencert Negative Control #1 siRNA). After the third sequence, the si-MDR1 3564-3574, was selected as a target for subsequent analysis, another siRNA duplex with one base-pair mutation was also synthesized as control for the specificity of knockdown experiments (Fig  1a) . The siRNA duplexes were transfected according to the recommended procedure by using the Oligofectamine Reagent (Invitrogen Life Technologies, Carlsbad, CA). Silencing was examined 24-48 hours after transfection.
Reverse transcription-polymerase chain reaction (RT-PCR)
Total RNA was extracted from siRNA-treated cells (K562/A02, 1 Â 10 6 ) using TRIzol reagent (Invitrogen Life Technologies, Carlsbad, CA). A measure of 2.5 mg RNA was used to synthesize cDNA using the Superscript First-Strand Synthesis System (Invitrogen Life Technologies, Inc.) in a final volume of 50 ml of random primer (GIBCOBRL). 13 For detection of MDR1 transcript 2 ml cDNA was used in 50 ml reaction using MDR1 primer (5 0 -TTACACGTGGTTGGAAGC-3 0 5 0 -CATAGATCAGCAG GAAAG-3 0 ). Testing for the presence of b-actin (primer:
0 ) acted as a control for amplifiable RNA. Amplification cycles were: 941C for 5 minutes, then 25 cycles at 941C for 1 minutes, 581C for 1 minute, 721C for 1 minute, followed by 721C for 10 minutes. A volume of 10 ml PCR reaction was electrophoresed on a 2% agarose gel, and the amplified DNA band was visualized by ethidium bromide staining. The amplification products of MDR1 and b-actin were 300 and 548 bp, respectively.
Flow cytometry
The cells were stained according to the method reported previously 14 using anti-P-glycoprotein PE (BD Biosciences). Add 20 ml of reagent to 50 ml of whole blood, mix thoroughly and incubate for 20 minutes in a dark at room temperature. After two further washes with phosphate buffered saline (PBS), flow cytometric analysis was performed using an Epics-Profile II flow cytometry (Coulter Co, Miami, FL). The P-gp positivity was determined by the Epics Elite software Immuno 4 computer program.
Western blot analysis
Total cell lysates were made as described previously. 15 Protein concentrations were determined with a Bio-Rad protein assay (Bio-Rad, Richmond, CA). A total measure of 50 mg of cell lysates were fractionated on an 8% SDSpolyacrylamide gel and transferred onto a nitrocellulose membrane by electroblotting. After blocking with Trisbuffered saline/0.1% Tween-20 containing 10% fat-free milk, blots were incubated overnight in Tris-buffered saline/0.1% Tween20 containing 1% fat-free milk. The Inhibition of MDR1 gene expression by siRNA Z Peng et al membranes were incubated 2 hours at 41C with 1:500 p170/MDR Ab-2 (NeoMarkers, Inc, Fremont, CA) or 1:400 anti-actin (Santa Cruz, CA) in 5 g/100 ml skimmed milk PBS containing 0.1 g/100 ml Tween 20. Protein was visualized by enhanced chemiluminescence (Amersham Biosciences) after incubating with horseradish peroxidaseconjugated goat and mouse IgG secondary antibody (1/600) (Santa Cruz).
Intracellular daunomycin accumulation
Steady-state daunomycin (DNR) accumulation was assayed by a method described previously 16 with some modifications. Briefly, MDR K562/A02 cells (0.5 Â 10 6 / ml) transfected siRNAs were seeded in 24-well plates and grown for 48 hours. Then, efflux was measured after 60 minutes with 1 mg/ml DNR (Sigma) at 371C. Flow cytometric analysis was performed after two further washes with ice-cold PBS. DNR was excited by argon laser at 488 nm and the orange/red fluorescence signal was collected through a 585/42 bandpass filter set (FL-2 height). The relative level of intracellular DNR was determined by the mean fluorescence intensity (MFI) of gated leukemic cells.
Chemosensitivity test analysis
The MTT assay was carried out as previously described. 17, 18 . Briefly, 5 Â 10 5 cells cells of K562/A02 and K562 were plated in 96-microwell plates containing serial dilutions (0.01 mg/mlB100 mg/ml) of ADM, VCR and VP-16 in a total volume of 200 ml/ well and incubated for 72 hours. Following exposure to the chemotherapeutic drugs, 20 ml of a MTT (Sigma) solution (5 mg/ml) was added to the cells in each well and incubated for 4 hours. To pack cells to the base of wells, plates were centrifuged at 200 g for 5 minutes and the bulk of the medium removed. A volume of 100 ml DMSO was then added to each well to disrupt the cells and dissolve the crystalline formazan deposits. Plates were agitated gently on a plate shaker for 10 minutes, then absorbance (A) read at 548 nm. The IC 50 for drugs, the concentration that produced 50% inhibition of colony formation compared to vehicle-control well, were determined.
Results
Selection of anti-mdr1 siRNAs
The small interference RNAs (siRNAs) targeting three different sequences (445-465, 2472-2492, 3564-3584, GenBank accession number AF016535) were designed to screen the most effective targeted sequence. The third sequence (si-MDR1, Fig 1) significantly reduced the MDR1 mRNA (Fig 1b) and P-gp protein levels (Fig 1c) as compared with the two others and the random sequence control siRNA. The third sequence (si-MDR1) was therefore selected as a target for subsequent analysis.
Reduction of MDR1 mRNA expression by siRNA
After exposure to si-MDR1, the number of K562/A02 cells were not significantly affected. However, it was found by RT-PCR that at 24 or 48 hours after transfection si-MDR1, the magnitude of the MDR1 transcript of K562/A02 cells was significantly decreased compared with that of cells treated with si-MDR1-mut and cells without treatment with siRNA (Fig 2a) . The MDR1 mRNA expression was slightly changed with time. As a control, the si-MDR1-mut was unable to reduce the 
Knockdown of P-gp protein by siRNA
We examined whether the P-gp was silenced in K562/A02 cells, which would correspond to the significant reduction of the MDR1 mRNA after transfection of si-MDR1. As seen in Figure 2b , Western blot analysis did not detect Pgp expression in K562 cells but revealed a high P-gp expression in K562/A02 cells. As expected, P-gp was reduced to a very low level after treatment of K562/A02 cells with si-MDR1. In contrast, P-gp expression in K562/ A02 cells treated with si-MDR1-mut was almost as high as that of K562/A02 cells without siRNA treatment.
The P-gp expression was further analyzed using flow cytometry. It was found that P-gp expression rate was In the presence of si-MDR1(200 nM), the levels of P-gp was significantly decreased [37.88(77.70 )%] as compared to si-MDR1-mut(Po.01) (Fig 3) .
Inhibition of P-gp function in si-MDR1-treated K562/A02 cells
The relative levels of intracellular DNR, one of P-gp transportable drugs, were determined by the mean fluorescent intensity levels (MFI) of gated leukemic cells. As shown in Figure 3 , P-gp expression was related inversely with MFI. K562/A02 cells treated with the siRNAs were seeded in 24-well plates and grown for 48 hours. The accumulation of DNR (MFI) was quantified by the flow cytometric method. Treatment of cells with the si-MDR1 significantly enhanced intracellular drug accumulation (MFI 73.79, Po.01) and inhibited the P-gp expression as compared si-MDR1-mut (MFI 39.82, Po.01). The MFI in K562/A02 (37.66, P4.05) was almost the same as that of si-MDR1-mut.
Restoration of chemotherapeutic sensitivity of the k562/ A02 cells
To assess whether siRNA-directed suppression on P-gp expression sensitized MDR leukemic cells to cytotoxic agents, we compared the drug sensitivity of the si-RNAstreated K562/A02 cells. The sensitivity of the K562/A02 cells to ADM, VCR and VP-16 was determined using MTT (Table 1) . In K562/A02 cells, si-MDR1 caused about four-fold reversal of cellular resistance to ADM, 11-fold to VCR and 17-fold to VP-16.
Discussion
Recent work by Tuschl and colleagues 8 had shown that siRNAs can induce silencing in numerous mammalian cell lines, presumably by entering the RNAi pathway. The remarkable potency of the RNAi reaction enables a complete ''knock-down'' of a specific protein and especially considering that RNAi has repeatedly proven itself to be more robust than antisense techniques because it works more often and typically decreases expression of a gene to a lower level, therefore, may overcome some of the initial problems with conventional antisense strategies. 9, 19 The siRNAs are highly sequence-specific reagents and discriminate between single mismatched targeting RNA sequences, and may represent a new avenue for gene therapy. Herein, several groups 12, [19] [20] [21] report that the expression of mRNA coding for mutated proteins, which give rise to leukemia and lymphomas, could be decreased or blocked completely by specific siRNAs.
The overproduction of P-gp causes not only an increase in drug excretion from cells, but also a decrease in intracellular drug accumulation, thereby reducing the intracellular drug contents such as ADM, VP-16 and VCR. 15, 22, 23 In the attempt to circumvent the ''classical'' MDR phenotype, several new approaches have recently been developed for the eradication of P-gp-expressing MDR cells. These approaches include monoclonal antibodies such as MRK16 24 or immunotoxins against Pgp, 25 antisense oligonucleotides for the specific inhibition of P-gp gene expression, 17 and the transcriptional decoy strategies. 26 The present study was designed to determine if siRNA against MDR1 gene can effectively inhibit expression of MDR1 gene product, P-gp. We first designed three different siRNAs targeting MDR1 gene and tested their effectiveness in silencing MDR1 mRNA expression. The results showed that transfection of one siRNA duplex (si-MDR1) caused a significant inhibition of MDR1 mRNA expression in human MDR cell line K562/A02. The reduction of P-gp expression was then detected in K562/ A02 cells by Western blot and flow cytometry analysis. A significant suppression of P-gp expression by si-MDR1 was observed. We have noted that the inhibition induced by si-MDR1 was not complete and a maximal suppression was around 60%. This may be due to a relatively long half-life of P-gp (T 1/2 about 16 hours) 27 and to the transient nature of RNA transfer in siRNA mediatedtargeting experiments. 12, 28 The use of a DNA vectorbased siRNA expression system could overcome this limitation. 29, 30 Brummelkamp et al 30 used this approach to stably suppress p53 over a period of 2 months. Incorporation of siRNA expression cassettes into virus vector systems, such as retroviral vectors, 31 especially lentiviral vectors 32, 33 for gene transfer to nondividing cells, represents a powerful tool for functional genomics.
We then investigated whether the treatment with si-RNA could not only reduce P-gp expression level, but also recover the sensitivity to the P-gp transportable cytotoxic drugs, such as ADM, VCR and VP-16, in K562/ A02 cells. DNR retention is known as one of the most sensitive assays for P-gp function. 16 An increase of intracellular DNR retention in si-MDR1-treated cells was observed, confirming the inhibition of P-gp function by siRNA-targeted MDR1. The IC 50 values that obtained in K562/A02 cells after exposure to cytotoxic agents were found to be decreased only in the si-MDR1-treated K562/ A02 cells. The si-MDR1 caused about four-, 11-, 17-fold reversal of cellular resistance to ADM, VCR and VP-16, respectively. As shown in Table 1 si-MDR1 cannot completely restore the chemotherapeutic sensitivity of K562/A02 cells similar to that of K562, because of the incompleted supression of P-gp expression and another causes of drugs resistance. [34] [35] [36] In conclusion, the present work demonstrates that introduction of an MDR1-targeted si RNA duplex into drug-resistant leukemia cells can effectively inhibit the expression of MDR1 mRNA and P-gp, resulting in an increase in the intracellular accumulation of P-gp transportable chemotherapeutic drugs and in the sensitivity restoration of leukemia cells to the chemotherapeutic drugs. This approach may be applicable to leukemia or other cancer as a specific means to reverse tumor cells with a P-gp-dependent MDR phenotype back to a drugsensitive one. Successful delivery of siRNA to postnatal and adult mice has recently been reported. 37, 38 The observation that siRNA can effectively inhibit gene expression in mammals opens the door for exploring the use of siRNA in the treatment of human disease.
